Basic Information
| LncRNA/CircRNA Name | LINC00265 |
| Synonyms | NA |
| Region | GRCh38_7:39733632-39793092 |
| Ensemble | ENSG00000188185 |
| Refseq | NR_026999 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | acute myeloid leukemia |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, etc. |
| Sample | AML tissues, human leukemia cell lines HL-60,AML cell lines NB4 and human normal stromal cells HS-5 |
| Expression Pattern | up-regulated |
| Function Description | LINC00265 was significantly highly expressed in the bone marrow and serum of AML patients. High serum LINC00265 was significantly associated with FAB classification and cytogenetics. ROC analyses showed that serum LINC00265 levels were reliable in distinguishing patients with AML from normal controls. Clinical assay indicated that AML patients with higher serum LINC00265 expression suffered poorer overall survival. Functionally, overexpression of LINC00265 suppressed the capability of proliferation, migration and invasion in AML cell lines. By using Western blot, we further illustrated that LINC00265 activated PI3K/AKT signaling in AML cell lines. |
| Pubmed ID | 30536332 |
| Year | 2018 |
| Title | Long noncoding RNA LINC00265 predicts the prognosis of acute myeloid leukemia patients and functions as a promoter by activating PI3K-AKT pathway |
External Links
| Links for LINC00265 | GenBank HGNC NONCODE |
| Links for acute myeloid leukemia | OMIM COSMIC |